The patent (patent number: 10-2592716) will provide an exclusivity period until
Corresponding patent applications have previously been granted in
For more information:
Phone: +46 8 122 038 50
E-mail: jenny.sundqvist@indexpharma.com
Johan Giléus, Deputy CEO and CFO
Phone: +46 8 122 038 50
E-mail: johan.gileus@indexpharma.com
Publication
The information was submitted for publication through the agency of the contact person set out above at
InDex is a pharmaceutical development company focusing on immunological diseases where there is a high unmet medical need for new treatment options. The company's lead asset is the drug candidate cobitolimod, which is being evaluated in the phase III program CONCLUDE as a novel treatment of moderate to severe left-sided ulcerative colitis - a debilitating, chronic inflammation of the large intestine. InDex has also developed patent protected discovery stage substances, so called DNA based ImmunoModulatory Sequences (DIMS), with the potential to be used in the treatment of various immunological diseases.
InDex is based in
The information in this press release is intended for investors.
https://news.cision.com/index-pharmaceuticals/r/index-pharmaceuticals-has-been-granted-a-new-patent-for-cobitolimod-in-south-korea,c3857940
https://mb.cision.com/Main/9612/3857940/2375583.pdf
(c) 2023 Cision. All rights reserved., source